OBJECTIVE: To investigate the current status of medical treatments for patients with chronic stable angina pectoris (SA) and the gaps between clinical practice and guidelines in mainland of China. METHODS: This was a multicenter cross-sectional survey. Each investigator enrolled at least 50 consecutive outpatients with SA who were diagnosed and treated for at least one month. A standardized questionnaire including information on patients characteristics, risk factors, complicating diseases and current medication was filled out by investigator for each individual patient. RESULTS: One thousand eight hundred and thirty questionnaires were collected from 29 hospitals and 1809 intact records were used for final analysis. Mild and moderate angina (CCS I or II) were still present in 79.6% patients, 91.3% patients were treated with aspirin, 37.4% with clopidogrel, 64.6% with β blocker, 50.3% with angiotensin-converting enzyme inhibitor (ACEI), 20.1% with angiotensin II receptor blocker (ARB), and 65.3% with statin. CONCLUSION: In general, guidelines were followed in the medical treatments of SA in the mainland of China and improved compared with the survey data obtained 10 years ago; however, there are still gaps between current clinical practice and guidelines, the insufficient use of β-blocker and statin for SA patients is especially significant.
OBJECTIVE: To investigate the current status of medical treatments for patients with chronic stable angina pectoris (SA) and the gaps between clinical practice and guidelines in mainland of China. METHODS: This was a multicenter cross-sectional survey. Each investigator enrolled at least 50 consecutive outpatients with SA who were diagnosed and treated for at least one month. A standardized questionnaire including information on patients characteristics, risk factors, complicating diseases and current medication was filled out by investigator for each individual patient. RESULTS: One thousand eight hundred and thirty questionnaires were collected from 29 hospitals and 1809 intact records were used for final analysis. Mild and moderate angina (CCS I or II) were still present in 79.6% patients, 91.3% patients were treated with aspirin, 37.4% with clopidogrel, 64.6% with β blocker, 50.3% with angiotensin-converting enzyme inhibitor (ACEI), 20.1% with angiotensin II receptor blocker (ARB), and 65.3% with statin. CONCLUSION: In general, guidelines were followed in the medical treatments of SA in the mainland of China and improved compared with the survey data obtained 10 years ago; however, there are still gaps between current clinical practice and guidelines, the insufficient use of β-blocker and statin for SA patients is especially significant.